Literature DB >> 20108541

The importance of residual renal function in chronic dialysed patients.

Daniela Rădulescu1, Dumitru Ferechide.   

Abstract

In the last decade, many researches have reached to the conclusion that preservation of residual renal function (RRF) is important after initiating dialysis, as well as in the predialysis period. RRF has been proven to contribue to the quality of life of dialysis patients. Longer preservation of RRF provides a better small and middle molecule removal, improved volemic status and arterial pressure control, diminished risk of vascular and valvular calcification due to better phosphate removal. Deterioration of RRF results in worsening of anemia, inflammation and malnutrition. It is now proven a direct relationship between RRF value and survival in dialysis patient. Several therapeutical intervention have been proven to ameliorate the decline of RRF in dialysis patients. Some of them are identical with those before initiating dialysis: ACE-inhibitors and/or angiotensin-receptor blockers, limiting the use of nephrotoxic drugs, avoiding contrast media procedures, adequate control of blood pressure. Others are specific for dialysis period: adequate dialysis dose, avoiding excessive ultrafiltration, preventing arterial hypotension during dialysis sessions, using biocompatible dialysis membranes, ultrapure water for dialysis, dietary interventions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20108541      PMCID: PMC3018976     

Source DB:  PubMed          Journal:  J Med Life        ISSN: 1844-122X


Measurement of RRF

The exact value of RRF is necessary both at the moment of initiating dialysis therapy and on the course of the dialytic therapy in order to adjust, simultaneous with the RRF decrease, the dose of dialysis. The value of remaining diuresis do nor correlate with RRF[1. The inuline clearance is the standard method to which other GFR measurements are compared, but it is expensive, especially when it has to be repetead at regular intervals during the dialytic therapy[2 The creatinine clearance is frequently used in current practice for GFR estimation, but it has limits: the creatinine depends not only on the glomerular filtration rate, but also on the muscular mass and individual's age; within the kidney, besides free glomerular filtration, creatinine suffers tubular secretion too, which becomes significant as the renal function deteriorates; in uremics, creatinine extrarenal (intestinal) elimination is present too. In addition, the usual method of measuring plasma creatinine (with alkaline picrat) may give results that are falsely higher because of the non–creatinine cromogens. As a result, creatinine clearance, calculated by the classical formula UxV/P, overestimates the GFR real value[1]. The blood urea or urea clearance are even less precise for GFR estimation. The production of urea depends on diet, proteic catabolism, and the excretion is influenced by diuresis. Within the kidney, urea, after glomerular filtration, suffers tubular reabsorption. Urea clearance underestimates the real value of GFR. Cockcroft and Gault formula for creatinine clearance has been developed in order to exceed the limits of the classical formula (UxV/P),but this formula allows a prediction only for the endogene creatinine, not for the GFR[3, 4].The inhibiton of the creatinine tubular secretion with cimetidine may provide assessments close to the real ones, but the necessary doses are very high and there can't be achieved a complete blocking of tubular secretion. In addition,for hemodialysed patients, the blocking of tubular secretion of creatinine by cimetidine won't take effect [3] MDRD formula (modification of diet in renal disease) is not usefull in estimating RRF in dialysed patients, because it overestimates the real values, sometimes with 100%[5]. Clearance of beta2 microglobulin or cistatine may represent an alternative of RRF estimation, because they are excreted only by glomerula filtration, but their use in dialysed patients hasn't come into the current use yet6,]. GFR isotopic markers –125I–iothalamate,99mTc–DTPA or 51Cr–EDTA–have the advantage of simplicity and avoid urine collection, but may overestimate real GFR as they are eliminated by extrarenal routes too and have a large volume of distribution; besides, they are expensive[7].The overestimation of real GFR, by approximately 20% in patients with normal renal function,increases as the renal function deteriorates. Iohexol clearance represents a method of GFR value estimation without a risk of affecting the remaining kidney function, but it is also expensive[8] Numerous studies show a good correlation between the arithmetic mean of creatinine and urea clearance and RRF real value[7];clearances are calculated by the classical formula (UxV/P). This method is cheap and easy to repeat, depending only on patient's compliance. For HD patients, plasma values for urea and creatinine are measured one of the days between the dialysis sessions, when urine is collected for 24 hours.

RRF and mortality risk in dialysis patients

Several researches demonstrated that preservation of RRF is associated with better survival rate, both in PD and HD patients. CThe first research emphasizing that RRF has an influence on survival of PD patients was performed in 1995 by Maiorca[9], who studied RRF as an independent factor, demonstrating that the persistence of a significant renal clearance is accompanied by a longer survival in PD patients. Subsequent studies[10,11,12,]. revealed that RRF and not the dialysis dose is predictive for a longer survival of PD patients. CANUSA study (Canada–USA Peritoneal Dialysis Study Group), whose results were published in 1996[13]and which started with the premise of an equivalence between RRF and PD clearance, demonstrated that the sum of the two clearances (RRF + PD) for small molecules is a predictor irrespective of other factors for the mortality of PD patients. Reanalysis[14,]of the data of CANUSA study in 2001 showed that RRF and not the dose of dialysis is the one that directly influences patients' survival. Other researches [15,16] demonstrated the same relation between RRF and survival rate in HD patients. In 2002, the ADEMEX (ADEMEX = ADEquacy of Peritoneal Dialysis in MEXico) study, performed in PD patients, has reached to the conclusion that residual renal clearance and the dialytic clearance are not equivalent and additive [17 ].Increasing solvite clearance in DP was not accompanied with better survival rate in overall or anuric patients, demonstrating that RRF was the one that directly influenced patients' survival rate. This observation led to the conclusion that preserving RRF has additional metabolic benefits, beyond better low molecular solvites removal. Indeed, subsequent studies[ 18]demonstrated an increased frequency in anurics, compared to patients with preserved RRF, of numerous metabolic and cardiovascular complications: more severe anemia, increased frequency of erythropoietin resistance, higher CaxP product, increased rate of malnutrition, inflammation, and ventricular hypertrophy. Impact of RRF upon volemic status and cardiac hypertrophy. Extracellular liquid volume is increased in peritoneal dialyzed patients with residual GFR below 2mL/min than in patients with residual GFR above 2mL/min[19]. In the reanalyse of CANUSA study [ 14],every 250mL of urine was associated with 36% reduction in global mortality for PD patients. These data–indirectly–emphasized that the kidney, even in advanced stages of functional insufficiency, has a major importance in eliminating water and sodium.Subsequently, the study done by Ates and collaborators[20].confirmed that the value of sodium and water fractionalexcretion has a predictive value for the mortality of PD patients. PD patients with history of hidrosaline retention show degrees of more severe hypertrophy and cardiac dilatation, as well as more important alternation both of systolic and diastolic function than in the patients with controlled volemia, as other recent studies demonstrate[21,22].Considering that cardiac hypertrophy is an important factor of mortality prediction for chronically dialysed population, the data above suggest that cardiovascular complications,which are more frequent among anuric dialysed patients, are, at least partly, due to the inefficient control of volemia after RRF loss. In PD patients, arterial hypertension is more difficult to control as RRF decreases [22 ,23] In addition, the same studies note that as RRF decreases, other complications appear; the anemia becomes more severe (with increased erythropoietin needs), hypoalbuminemia is aggravating, the arterial pressure pulse increases. All those data suggest that RRF influence on cardiac hypertrophy is due not only to water and salt elimination, but also to other effects such as a better purification of uremic toxins. In predialysis CRF patients, left ventricle (LV) mass increases parallel with the decrease in residual GFR [24]; initiating PD led to the regression of left ventricular hypertrophy (LVH) and improvement of the cardiac function [25]. The evidence that residual renal clearance for solvents with low MW and not the peritoneal clearance is the one that directly influences LVH [22], as well as the fact that LVH regresses post–transplant[26], permitted the observation that there are certain non–dialysing uremic toxins which mediates LVH in peritoneal dialysed patients. There are a few studies [27,28] referring to RRF influence on volemia and cardiovascular status in HD patients. All demonstrate a directly proportional relation between RRF preservation and the control of volume–dependent hypertension and volemia.

RRF and calcium–phosphate balance

Most of the studies demonstrate a better phosphate control in PD versus HD [29,30] as a result of better removal of phosphate and better preservation of RRF. In PD patients the presence of hyperphosphatemy is closely related with RRF rate: only 1/3 of the patients with preserved RRF show increased values of seric phosphates, while over 1/2 of anurics have hyperphosphatemy. Anurics also have an increased inflammatory status; the association of hyperphosphatemia and hypercalcemia leads to the increase of valvular calcification risk, vascular wall stiffening, high degree of cardiac hypertrophy [30]. A study published by Wang and collab. in 2005 in Nephrology Dialysis Transplantation [31] connects valvular calcification predisposition to fetuin–A depletion, a circulatory inhibitor of calcification and a negative reactant of the acute stage. On the other hand, the authors did not find an association between fetuin–A depletion and RRF reduction and they conclude that in anuric peritoneal dialysed patients, fetuin–A depletion is not responsible for increased frequency of valvular calcification.

Inflammation and RRF

The presence of inflammation is noted with increased frequency (between 12–65%) in chronic dialysed patients [32]. The inflammation degree, estimated by C-reactive protein [33 ,34] or interleukin–6 dosing [35,36] directly influences dialysed patients' survival rate and cardiovascular mortality. In predialysis uremic patients it was reported an inversely proportional relation between RRF and plasma concentration of pro-inflammatory mediators [ 40]. Similar results were published in PD patients: RRF decrease is associated with the increase of inflammatory response [39] estimated by C–reactive protein dosing [37] or by the sanguin level of a soluble vascular cell adhesion molecule [38]. All the studies indicate that the relation between RRF and the degree of inflammation is independent of patient's cardiovascular status [41]. The mechanism through which RRF loss worsens the inflammation of chronically dialysed patients seems to be, as some studies on animals indicate, oxidative stress of vascular endothelium with the activation of monocytes and cytokines[42,43]. A vicious circle takes place: inflammation worsens,at its turn, the deterioration of RRF [44]. The association of inflammation with LVH and RRF loss has an additive effect on cardiovascular complications rate in dialysed patients [39].

The contribution of RRF to the nutritional status

Malnutrition is frequent in chronic dialysed patients and represents an independent factor which influences mortality, especially by cardiovascular diseases. The preservation of diuresis and implicitly of a significant RRF permits a more liberal hygieno–dietetic regimen. Using systems of nutrition estimation that are subjective [45,46,47] – questionnaires on alimentary supply, good condition, etc or objective– dry body mass, seric albuminemia [47,48], most of the studies concluded that the proteic and energetic dietary amount, as well as the vitamins dietary amount are inversely correlated with RRF value. Other researches demonstrated a direct relation, independent of the dialysis dose, between RRF reduction and the appearance of malnutrition, which suggests that native kidney removes some non–dialysable uremic toxins with medium MW. RRF loss is also accompanied by a increased resting energy expenditure [49], which can lead to malnutrition unless there is a compensatory increase in energetic and proteic dietary regimen. The general and cardiovascular mortality risk correlates with increased basal energetic expenditure. The determinant link in the relation malnutritioninflammationatherosclerosis–increased cardiovascular mortality seems to be the loss of RRF; increasing the dialytic clearance has no benefits.

The importance of RRF in removal of uremic toxines

Preservation of a significant RRF allows a better removal of uremic toxins with medium molecular weight. Irrespective of the dialysis type, beta 2 microglobulin level is lower in dialysed patients with preserved RRF [50,51,52]. In anuric PD patients, increasing the dialysis dose is followed by a better removal of toxins with low MW, but not of those with medium MW and other toxins that circulate bound to proteins–such a s P–cresol [53,54].

FRR and quality of life in dialysed patients

Considering all the factors that favorably influence RRF preservation in chronic dialysed patients, one may conclude that the quality of life, not only the survival period is ameliorated. The patient with preserved RRF has a more liberal diet, a better compliance to potassium and hidrosaline restrictions or to the drug regimens. A lower rate of complications needs less drugs, which has better psychological and financial impact. A better social and familial insertion is achieved, the sensation of handicap which is present in most dialysed patients due to the dependency upon extrarenal purification therapy is diminished or absent. Of course, there is a large individual variability which especially depends on patient's age and existing co–morbidities; the advanced age, the coexistence of generalized manifestations of atherosclerosis, predialitic cardiovascular diseases, etc are a few examples in which the RRF influence on chronic dialysed patient's life is insignificant. NECOSAD study [55] demonstrated, in PD patients, a positive influence of RRF preservation on the most dimensions of life quality: physical functions, vitality, uremic symptoms, sleeping disorders; in the same study, the dialysis clearance had no influence on these dimensions.

Preservation of RRF in chronic dialysed patients

All the researches performed until present [56,57, 58,59] indicate a better preservation of RRF in PD versus HD,which gave birth to the concept of ‘integrative care approach’ of CRF patient: patients with preserved RRF will initially be oriented to PD and, after losing RRF, transferred on HD. A retrospective study performed in 2000 on a large number of patients (‘Van BW, Vanholder RC, Veys Net al’. An evaluation of an integrative care approach for end–stage renal disease patients. ‘J Am Soc Nephrol 2000’)demonstrated that such an attitude is accompanied by a better survival rate in PD patients transferred on HD as compared to those that remained on PD or as compared to those who begun on HD from the beginning [60]. The superiority of PD in preserving RRF can be explained through two factors: Better hemodynamic stability in PD, which decreases renal ischemic aggressions. In 2000, Moist demonstrated that higher values of postdialytic medium hypertension are associated with a better RRF preservation in chronic HD [ 59]. In NECOSAD study [55], there was demonstrated a relation between the frequency of intradialytic hypotension episods and the rate of RRF decline; the periods of volemic depletion were associated with a more rapid deterioration of RRF. Nephrotoxic effects of the pro–inflammatory mediators released within the extracorporeal circuit of HD. On the other hand, recent researches [61,62] demonstrated that, using biocompatible hemodialysis membranes and ultrapure water, RRF decline is similar to the one in the continuous ambulatory peritoneal dialysis. RRF decrease is more rapid in patients hemodialysed with cellulose membranes as compared to patients hemodialysed with high-flux polisulfone [63]. Foreign substances present within incompatible membranes, in contact with blood, stimulate mononuclear and complement activating [63]. Some recent studies [64,65] suggest a more rapid deterioration of RRF in patients receiving automatic peritoneal dialysis (APD) versus those on continuous ambulatory peritoneal dialysis (CAPD) and explain this through the intermittent nature of automatic peritoneal dialysis (APD) which produces a osmotic and volemic chargeless steady than in CAPD. Other researches [59,66, 67] consider these observations as groundless because of the non-uniform selection of patients in ADP. Irrespective of the type of PD, the rate of RRF decline is correlated with the frequency of peritonitis episodes [44] and with the type of dialysis solution. Avoiding nephrotoxic drugs–non–steroidal anti–inflammatories, aminoglicosides etc– is not only a predialytic measure of preventing CRI progression, but it also must be done after the dialysis initiation in order to preserve RRF. If investigations with contrast media are needed, all the prophylactic measures must be taken [68]: adequate hydration (eventually HD immediately after the procedure for adequate ultrafiltration), the minimum necessary dose, prophylactic treatment with acetilcisteine [69,70], preferring hypo–osmolar non–ionic contrast substances [69]. In PD patients, the administration of aminoglycosides is accompanied in some of the studies by an acceleration of RRF decline [71], while in other studies [72,73] it had no influence, which is explainable through the intermittent administration of intraperitoneal treatments. A recent study [73] compared the influence on RRF of intraperitoneal regimen for peritonitis with ceftazidime versus netilmicine (6 weeks, administrated once daily) and didn't find any difference. The administration of diuretics in chronic dialysed patients is accompanied by an increase of diuresis and decrease of hidrosaline retention, but doesn't influence RRF [74,75,76]. ACEs inhibitors or/and angiotensin receptors blockers may have the same renoprotective effects as in predialysis [77,78]. Regardless of the drug regimen, controlling systemic hypertension is accompanied by longer preservation of RRF. In the same time, performing excessive ultrafiltration compromises in time RRF [79,80]. Therefore, excessive ultrafiltration, intradialytic hypotension and semnificative interdialytic weight gain should be avoided.
  78 in total

1.  Acute effects of high-dose furosemide on residual renal function in CAPD patients.

Authors:  Rudolf W van Olden; Henk-Jan Guchelaar; Dirk G Struijk; Raymond T Krediet; Lambertus Arisz
Journal:  Perit Dial Int       Date:  2003 Jul-Aug       Impact factor: 1.756

2.  Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD.

Authors:  Will McKane; Shahid M Chandna; James E Tattersall; Roger N Greenwood; Ken Farrington
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

3.  Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis.

Authors:  Angela Yee-Moon Wang; John Sanderson; Mandy Man-Mei Sea; Mei Wang; Christopher Wai-Kei Lam; Philip Kam-Tao Li; Siu-Fai Lui; Jean Woo
Journal:  Am J Clin Nutr       Date:  2003-04       Impact factor: 7.045

4.  Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.

Authors:  Ramón Paniagua; Dante Amato; Edward Vonesh; Ricardo Correa-Rotter; Alfonso Ramos; John Moran; Salim Mujais
Journal:  J Am Soc Nephrol       Date:  2002-05       Impact factor: 10.121

5.  Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.

Authors:  Philip Kam-Tao Li; Kai-Ming Chow; Teresa Yuk-Hwa Wong; Chi-Bon Leung; Cheuk-Chun Szeto
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

6.  Associations between circulating inflammatory markers and residual renal function in CRF patients.

Authors:  Roberto Pecoits-Filho; Olof Heimbürger; Peter Bárány; Mohamed Suliman; Ingela Fehrman-Ekholm; Bengt Lindholm; Peter Stenvinkel
Journal:  Am J Kidney Dis       Date:  2003-06       Impact factor: 8.860

7.  The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD )-2.

Authors:  Fabian Termorshuizen; Johanna C Korevaar; Friedo W Dekker; Jeannette G van Manen; Elisabeth W Boeschoten; Raymond T Krediet
Journal:  Am J Kidney Dis       Date:  2003-06       Impact factor: 8.860

8.  Acetylcysteine for prevention of contrast nephropathy: meta-analysis.

Authors:  Rainer Birck; Stefan Krzossok; Florian Markowetz; Peter Schnülle; Fokko J van der Woude; Claude Braun
Journal:  Lancet       Date:  2003-08-23       Impact factor: 79.321

9.  Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients?

Authors:  Angela Yee-Moon Wang; Jean Woo; Christopher Wai-Kei Lam; Mei Wang; Mandy Man-Mei Sea; Siu-Fai Lui; Philip Kam-Tao Li; John Sanderson
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

10.  A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients.

Authors:  Angela Yee-Moon Wang; Mei Wang; Jean Woo; Man-Ching Law; Kai-Ming Chow; Philip Kam-Tao Li; Siu-Fai Lui; John Elsby Sanderson
Journal:  Kidney Int       Date:  2002-08       Impact factor: 10.612

View more
  3 in total

1.  Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis.

Authors:  Kuang-Wei Huang; Hsin-Bang Leu; Jiing-Chyuan Luo; Wan-Leong Chan; Ming-Chih Hou; Han-Chieh Lin; Fa-Yauh Lee; Yi-Chun Kuan
Journal:  Dig Dis Sci       Date:  2013-12-08       Impact factor: 3.199

2.  Determining factors of diuresis in chronic kidney disease patients initiating hemodialysis.

Authors:  A-M Nechita; D Rădulescu; I Peride; A Niculae; O Bratu; D Ferechide; A Ciocâlteu; I A Checheriță; D Mischianu
Journal:  J Med Life       Date:  2015 Jul-Sep

3.  The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy.

Authors:  Ylenia Ingrasciotta; Janet Sultana; Francesco Giorgianni; Achille Patrizio Caputi; Vincenzo Arcoraci; Daniele Ugo Tari; Claudio Linguiti; Margherita Perrotta; Andrea Nucita; Fabio Pellegrini; Andrea Fontana; Lorenzo Cavagna; Domenico Santoro; Gianluca Trifirò
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.